Request Trial
27 November 2025FeaturesBig PharmaAmanda Simons

The clinical trial dilemma: Navigating European practice

Clinical trials create a patent paradox. With EPO case law rapidly reshaping the 'expectation of success' test—most recently T136/24—the line between innovation and obviousness is blurred. Amanda Simons of J A Kemp offers drafting strategies to secure protection for your downstream innovations.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Week Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Atif Choudhury at achoudhury@lifesciencesipreview.com 


More on this story

Big Pharma
What’s at stake in Australia’s biggest pharma patent appeal in years?
1 July 2026   The Otsuka v Sun Pharma appeal could redefine which pharmaceutical patents qualify for patent term extensions, with major implications for innovator companies, generic manufacturers and the future of market exclusivity in Australia.
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026   Despite a slowdown in US patent litigation, life sciences remains one of the most active sectors—but companies are using a wider than ever IP toolkit, says a new study.
Big Pharma
Novo Nordisk and OpenAI strike AI deal to boost drug discovery
15 April 2026   The Danish pharma giant is turning to artificial intelligence as it faces patent expiry, falling shares and intensifying competition from Eli Lilly.


Editor's picks

Pfizer’s US Paxlovid patent fight turns on a single error
Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026

Editor's picks

Americas
Pfizer’s US Paxlovid patent fight turns on a single error
25 June 2026
Biotechnology
Insilico lands potential $2.5bn AI biotech partnership
22 June 2026
Big Pharma
US life sciences damages averaged $33.5m between 2019-2025
18 June 2026
Americas
Hikma v Amarin: Six takeaways from the pivotal ruling
9 June 2026
Americas
Takeda to appeal $885m jury verdict over ‘pay-for-delay’ scheme
19 May 2026
Americas
UK govt backs DeepMind spinout’s $2.1bn plan to ‘solve all disease’ with AI
14 May 2026

More features

Vinson & Elkins grows West Coast patent and trade secrets bench
What’s at stake in Australia’s biggest pharma patent appeal in years?
Will Mounjaro and Zepbound get their first US generic rival?
Ashurst Perkins Coie opens its doors following landmark merger
Pfizer’s US Paxlovid patent fight turns on a single error
Novartis and Eli Lilly sign separate $1.9bn novel drug deals
Novo secures website blocking to tackle fake weight-loss drugs
GLP-1 patents and Africa: The COVID-19 lessons we still have not learned